Recent Developments in the Pathogenesis of COVID-19-associated Myocarditis

doi:10.12114/j.issn.1007-9572.2021.00.524

Abstract

Abstract: Severe acute respiratory syndrome coronavirus-2（SARS-CoV-2）was initially thought to mainly affect the respiratory system.A growing body of research has found that SARS-CoV-2 infection can affect multiple human organ systems，and heart is a major target organ secondary to lung.COVID-19-associated cardiac injury is often seen clinically，about 1%-7% of which is myocarditis.COVID-19-associated myocarditis often has a poor outcome.However，the possible pathogenesis mechanisms of COVID-19-associated cardiac injury，and its progression to COVID-19-associated myocarditis，as well as related pathophysiological changes are still unknown.Available data analysis has revealed that the recognized mechanism of cardiac injury in COVID-19 is ACE2-mediated cardiac injury，and cytokine storm-mediated or immune-mediated cardiac injury is only suggestive currently.Due to limited use of cardiac MRI and endocardial biopsy as well as insufficient autopsy findings and other basic research data in patients with COVID-19-associated myocarditis，the diagnosis and treatment of COVID-19-associated myocarditis are challenges that still exist for clinicians.We reviewed the possible pathophysiological mechanisms of COVID-19-associated myocarditis，which will contribute to improving medical workers' understanding of this disease so that its related mortality may be reduced.

Key words: COVID-19, SARS-CoV-2, Myocarditis, Myocardial injury, Pathogenesis, Review

摘要： 严重急性呼吸综合征冠状病毒2（SARS-CoV-2）最初被认为主要对呼吸系统产生影响，随着研究深入，目前已经发现SARS-CoV-2感染会影响人体的多个器官系统，心脏是继肺部感染之后的一大目标靶器官。临床上经常能观察到新型冠状病毒肺炎（COVID-19）患者的心脏损伤，其中心肌炎在COVID-19心肌损伤中占1%~7%，这类患者临床预后常较差。令人遗憾的是，目前COVID-19是如何引起心肌损伤，又是如何进展为心肌炎，其相关机制及病理生理改变目前仍未知。从目前资料分析发现，除血管紧张素转换酶2（ACE2）介导打击机制较为学者认可外，细胞因子风暴及免疫介导引发心肌损伤等机制目前仍是推测性的，鉴于心脏MRI、心内膜活检的应用受限，而COVID-19相关心肌炎的尸检等基础研究资料较少，因此，COVID-19相关心肌炎的诊断及治疗对临床医生而言仍是一大挑战。本文就COVID-19相关心肌炎可能存在的病理生理机制予以综述，以期有助于增进医务人员对该病的认识进而降低总体死亡率。

关键词: 新型冠状病毒肺炎, 新型冠状病毒, 心肌炎, 心肌损伤, 发病机制, 综述

LUO Fei,LI Shuren,HAO Xiao, et al. Recent Developments in the Pathogenesis of COVID-19-associated Myocarditis　[J]. Chinese General Practice, 2021, 24(20): 2589-2593. DOI: 10.12114/j.issn.1007-9572.2021.00.524.
罗飞,李树仁,郝潇等. 新型冠状病毒肺炎相关心肌炎发病机制的研究进展[J]. 中国全科医学, 2021, 24(20): 2589-2593. DOI: 10.12114/j.issn.1007-9572.2021.00.524.

References

［1］WANG D W，HU B，HU C，et al．Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan，China［J］．JAMA，2020，323（11）：1061-1069．DOI：10.1001/jama.2020.1585.
［2］SHI S B，QIN M，SHEN B，et al．Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan，China［J］．JAMA Cardiol，2020，5（7）：802-810.
［3］HALUSHKA M K，VANDER HEIDE R S.Myocarditis is rare in COVID-19 autopsies：cardiovascular findings across 277 postmortem examinations［J］．Cardiovasc Pathol，2021，50：107300.
［4］HUANG C L，WANG Y M，LI X W，et al．Clinical features of patients infected with 2019 novel coronavirus in Wuhan，China［J］．Lancet，2020，395（10223）：497-506.
［5］GUO T，FAN Y Z，CHEN M，et al．Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019（COVID-19）［J］．JAMA Cardiol，2020，5（7）：811-818．
［6］XU Z，SHI L，WANG Y J，et al．Pathological findings of COVID-19 associated with acute respiratory distress syndrome［J］．Lancet Respir Med，2020，8（4）：420-422．
［7］PUNTMANN V O，CARERJ M L，WIETERS I，et al．Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019（COVID-19）［J］．JAMA Cardiol，2020，5（11）：1265-1273．
［8］MAHAJAN K，CHANDRA K S.Cardiovascular comorbidities and complications associated with coronavirus disease 2019［J］．Med J Armed Forces India，2020，76（3）：253-260.
［9］OUDIT G Y，KASSIRI Z，JIANG C，et al．SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS［J］．Eur J Clin Invest，2009，39（7）：618-625．DOI：10.1111/j.1365-2362.2009.02153.x.
［10］POLLACK A，KONTOROVICH A R，FUSTER V，et al．Viral myocarditis——diagnosis，treatment options，and current controversies［J］．Nat Rev Cardiol，2015，12（11）：670-680．DOI：10.1038/nrcardio.2015.108.
［11］BABAPOOR-FARROKHRAN S，GILL D，WALKER J，et al．Myocardial injury and COVID-19：possible mechanisms［J］．Life Sci，2020，253：117723．DOI：10.1016/j.lfs.2020.117723.
［12］FERRARA J L，ABHYANKAR S，GILLILAND D G.Cytokine storm of graft-versus-host disease：a critical effector role for interleukin-1［J］．Transplant Proc，1993，25（1 Pt 2）：1216-1217.
［13］TAVAZZI G，PELLEGRINI C，MAURELLI M，et al．Myocardial localization of coronavirus in COVID-19 cardiogenic shock［J］．Eur J Heart Fail，2020，22（5）：911-915．
［14］SALA S，PERETTO G，GRAMEGNA M，et al．Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection［J］．Eur Heart J，2020，41（19）：1861-1862．DOI：10.1093/eurheartj/ehaa286.
［15］ZHYVOTOVSKA A，YUSUPOV D，FORONJY R，et al．Insights into potential mechanisms of injury and treatment targets in COVID-19，SARS-COV-2 infection［J］．Int J Clin Res Trials，2020，5（1）：147．DOI：10.15344/2456-8007/2020/147.
［16］Corrigendum to：coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin［J］．Eur Heart J，2021，42（2）：191．DOI：10.1093/eurheartj/ehaa248.
［17］FOX S E，AKMATBEKOV A，HARBERT J L，et al．Pulmonary and cardiac pathology in African American patients with COVID-19：an autopsy series from New Orleans［J］．Lancet Respir Med，2020，8（7）：681-686．
［18］ZHAO H，ZHU Q，ZHANG C，et al．Tocilizumab combined with favipiravir in the treatment of COVID-19：a multicenter trial in a small sample size［J］．Biomed Pharmacother，2021，133：110825．DOI：10.1016/j.biopha.2020.110825.
［19］FITZGERALD J C，WEISS S L，MAUDE S L，et al．Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia［J］．Crit Care Med，2017，45（2）：e124-131．DOI：10.1097/ccm.0000000000002053.
［20］LUO P，LIU Y，QIU L，et al．Tocilizumab treatment in COVID-19：a single center experience［J］．J Med Virol，2020，92（7）：814-818．DOI：10.1002/jmv.25801.
［21］HUBER S A.Autoimmunity in myocarditis：relevance of animal models［J］．Clin Immunol Immunopathol，1997，83（2）：93-102．DOI：10.1006/clin.1997.4342.
［22］BLAUWET L A，COOPER L T.Myocarditis［J］．Prog Cardiovasc Dis，2010，52（4）：274-288.
［23］ALHOGBANI T.Acute myocarditis associated with novel Middle east respiratory syndrome coronavirus［J］．Ann Saudi Med，2016，36（1）：78-80．DOI：10.5144/0256-4947.2016.78.
［24］NAKAGAWA K，NARAYANAN K，WADA M，et al．Inhibition of stress granule formation by middle east respiratory syndrome coronavirus 4a accessory protein facilitates viral translation，leading to efficient virus replication［J］．J Virol，2018，92（20）：e00902-00918．DOI：10.1128/JVI.00902-18.
［25］NARAYANAN K，HUANG C，LOKUGAMAGE K，et al．Severe acute respiratory syndrome coronavirus nsp1 suppresses host gene expression，including that of type I interferon，in infected cells［J］．J Virol，2008，82（9）：4471-4479．
［26］RUSSELL C D，MILLAR J E，BAILLIE J K.Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury［J］．Lancet，2020，395（10223）：473-475.
［27］LU R J，ZHAO X，LI J，et al．Genomic characterisation and epidemiology of 2019 novel coronavirus：implications for virus origins and receptor binding［J］．Lancet，2020，395（10224）：565-574．DOI：10.1016/S0140-6736（20）30251-8.
［28］WRAPP D，WANG N S，CORBETT K S，et al．Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation［J］．Science，2020，367（6483）：1260-1263．DOI：10.1126/science.abb2507.
［29］LUKASSEN S，CHUA R L，TREFZER T，et al．SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells［J］．EMBO J，2020，39（10）：e105114．DOI：10.15252/embj.20105114.
［30］WEVERS B A，VAN DER HOEK L.Renin-angiotensin system in human coronavirus pathogenesis［J］．Future Virol，2010，5（2）：145-161．DOI：10.2217/fvl.10.4.
［31］LIU P P，BLET A，SMYTH D，et al．The science underlying COVID-19：implications for the cardiovascular system［J］．Circulation，2020，142（1）：68-78.
［32］BIKDELI B，MADHAVAN M V，JIMENEZ D，et al．COVID-19 and thrombotic or thromboembolic disease：implications for prevention，antithrombotic therapy，and follow-up：JACC state-of-the-art review［J］．J Am Coll Cardiol，2020，75（23）：2950-2973．DOI：10.1016/j.jacc.2020.04.031.
［33］KIPSHIDZE N，DANGAS G，WHITE C J，et al．Viral coagulopathy in patients with COVID-19：treatment and care［J］．Clin Appl Thromb Hemost，2020，26：1076029620936776．DOI：10.1177/1076029620936776.
［34］MANOLIS A S，MANOLIS T A，MANOLIS A A，et al．COVID-19 infection：viral macro-and micro-vascular coagulopathy and thromboembolism/prophylactic and therapeutic management［J］．J Cardiovasc Pharmacol Ther，2021，26（1）：12-24．DOI：10.1177/1074248420958973.

[1]	WANG Tingting, TANG Yong, ZHANG Wenke, LI Zhigang. Research Progress on Exercise Intervention of Hyperuricemia [J]. Chinese General Practice, 2025, 28(30): 3841-3846.
[2]	ZHOU Sheng, DENG Changsheng, ZOU Guanyang, SONG Jianping. Research Progress on the Pathogenesis of Complications of Malaria in Cardiovascular Diseases [J]. Chinese General Practice, 2025, 28(27): 3466-3472.
[3]	SHEN Mingmei, LYU Yujiao, ZHANG Shangbo, ZHOU Xinchen, DONG Shuhan, ZHANG Zhuo, LIU Yongchao. Calcium Sensitive Receptors Mediate Signaling Pathways in Myocardial Injury [J]. Chinese General Practice, 2025, 28(18): 2301-2306.
[4]	CHEN Beibei, LI Jia, TAN Wenbin. Progress in the Research of Endocrine and Metabolic System Diseases and Secondary Osteoporosis [J]. Chinese General Practice, 2025, 28(17): 2082-2091.
[5]	DENG Jie, TAO Liyuan, LIU Nan, LI Jun, YAN Wenxin, QIN Chenyuan, LIU Qiao, DU Min, WANG Yaping, LIU Jue. Reliability and Validity of the Chinese Version of the Modified COVID-19 Yorkshire Rehabilitation Scale [J]. Chinese General Practice, 2025, 28(13): 1642-1648.
[6]	WANG Yuxin, PENG Wenwan, ZHOU Zheng, HUANG Haiyang, LU Xiaomin, DONG Mingguo. Research Progress on Cancer Risk and Its Pathogenesis of Gastric Precancerous Conditions [J]. Chinese General Practice, 2025, 28(11): 1411-1416.
[7]	FU Qiang, REN Zuolei, LIN Zhiqiang, GONG Jianfeng, WANG Changzheng, WANG Ting, HU Yalan, TAN Jufang. Imaging and Clinical Characteristics of 8 Cases of COVID-19 Complicated with Pneumomediastinum in Children [J]. Chinese General Practice, 2025, 28(04): 510-515.
[8]	HUANG Lihui, SHU Juan, TAO Huihui, BAO Hairong. Progress in Treatment of Post Inflammatory Pulmonary Fibrosis Induced by SARS-CoV-2 Infection [J]. Chinese General Practice, 2024, 27(32): 4085-4092.
[9]	ZHONG Minshan, SUN Wei, KONG Xiangqing. The Impact of Long COVID on Cardiovascular System: Clinical Manifestations, Mechanisms, and Principles of Diagnosis and Treatment [J]. Chinese General Practice, 2024, 27(27): 3325-3330.
[10]	LI Songjiao, LEI Kangchen, HUANG Hongwen, SONG Jiali, CHANG Yinghui, FAN Xiaonong, LI Li, DU Yuzheng, LIU Jian, CAI Xinru, BIAN Lina, MENG Lina, SONG Qian, SHEN Yan, GE Wenyi, LIU Wei, LI Yibing, JIA Hongbo, GAO Ying, MA Congcong. Investigation on Risk Factors and Main Symptoms of Long COVID and Their Influences on the Follow-up Research [J]. Chinese General Practice, 2024, 27(26): 3240-3248.
[11]	ZHANG Shan, ZHANG Meng, XU Xin, LIAO Lixin, SUN Mingjun, MA Haiyan, ZHANG Haibin, GUO Yuzhen. Advances in Pathogenesis, Diagnosis and Treatment of Ovarian Teratoma Associated Anti-N-methyl-D-aspartate Receptor Encephalitis [J]. Chinese General Practice, 2024, 27(24): 3038-3043.
[12]	JIANG Qixia, XIE Haoting, WANG Huajun, LI Xiuyun, ZHU Yuling, WANG Yaling, MIN Yan, WANG Ke. Effectiveness Analysis of Two Incontinence Care Plans Based on Guidelines for Elderly COVID-19 Patients with Incontinence [J]. Chinese General Practice, 2024, 27(18): 2212-2217.
[13]	Primary Healthcare and Health Education Committee of the Guangdong Provincial Health Management Association, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine. Expert Recommendations on the Diagnosis, Treatment, and Care of Post-COVID-19 Conditions for Primary Health Services: Guangdong Province [J]. Chinese General Practice, 2024, 27(17): 2045-2063.
[14]	XU Ziwei, CHENG Kangyao, GUI Li. A Scoping Review of Research on the Management of Surge Hospitals during a Major Infectious Disease Outbreak [J]. Chinese General Practice, 2024, 27(16): 2039-2044.
[15]	LI Zidong, ZHU Lin. Clinical Characteristics and Risk Factors of Fatigue in COVID-19 during Recovery Period [J]. Chinese General Practice, 2024, 27(15): 1849-1854.